A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control

Pharmacological Research

Volumn 111, Issue , 2016, Pages 272-282

  Simental Mendía, Luis E ^a   Sahebkar, Amirhossein ^b,c   Rodríguez Morán, Martha ^a   Guerrero Romero, Fernando ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Glucose control; Insulin sensitivity; Magnesium; Meta analysis

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; MAGNESIUM; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

BLOOD GLUCOSE MONITORING; CLINICAL ASSESSMENT TOOL; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HOMA-IR INDEX; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; ADULT; AGED; BLOOD; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DIETARY SUPPLEMENTS; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MAGNESIUM; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84976574147     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.06.019     Document Type: Review

References (67)

1. [1] George, B., Cebioglu, M., Yeghiazaryan, K., Inadequate diabetic care: global figures cry for preventive measures and personalized treatment. EPMA J 1 (2010), 13–18.
2. [2] Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., Lin, J.K., Farzadfar, F., Khang, Y.H., Stevens, G.A., Rao, M., Ali, M.K., Riley, L.M., Robinson, C.A., Ezzati, M., Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose), National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378 (2011), 31–40.
3. [3] Boyle, J.P., Thompson, T.J., Gregg, E.W., Barker, L.E., Williamson, D.F., Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr., 8, 2010, 29.
4. [4] Bergman, R.N., Ader, M., Huecking, K., Van Citters, G., Accurate assessment of β-cell function. The hyperbolic correction. Diabetes 51:Suppl. 1 (2002), S212–S220.
5. [5] Lopez Martinez, J., Sanchez Castilla, M., Garcia de Lorenzo y Mateos, A., Culebras Fernandez, J.M., Magnesium: metabolism and requirements. Nutr. Hosp., 12, 1997, 4.
6. [6] Paolisso, G., Scheen, A., D'Onofrio, F., Lefèbvre, P., Magnesium and glucose homeostasis. Diabetologia 33 (1990), 511–514.
7. [7] Paolisso, G., Barbagallo, M., Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am. J. Hypertens. 10 (1997), 346–355.
8. [8] Resnick, L.M., Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders: the mechanism of syndrome X. Am. J. Hypertens. 6 (1993), 123S–134S.
9. [9] Paolisso, G., Sgambato, S., Giuglinao, D., Torella, R., Varicchio, M., Scheen, A.J., D'Onofrio, F., Lefebvre, P.J., Impaired insulin mediated erythrocyte magnesium accumulation is correlated to impaired insulin-mediated glucose disposal in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 31 (1988), 910–915.
10. [10] Yajnik, C.S., Smith, R.F., Hockaday, T.D.R., Ward, N.I., Fasting plasma magnesium concentrations and glucose disposal in diabetes. Br. Med. J. (Clin. Res. Ed.) 288 (1984), 1032–1034.
11. [11] Dzurik, R., Stefikova, K., Spustova, V., Fetkovska, N., The role of magnesium deficiency in insulin resistance: an in vitro study. J. Hypertens. 9 (1991), S312–3.
12. [12] Dong, J.Y., Xun, P., He, K., Qin, L.Q., Magnesium intake and risk of type 2 diabetes meta-analysis of prospective cohort studies. Diabetes Care 34 (2011), 2116–2122.
13. [13] Larsson, S.C., Wolk, A., Magnesium intake and risk of type 2 diabetes: a meta-analysis. J. Intern. Med. 262 (2007), 208–214.
14. [14] Song, Y., He, K., Levitan, E.B., Manson, J.E., Liu, S., Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Diabet. Med. 23 (2006), 1050–1056.
15. [15] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., PRISMA Group, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535, 10.1136/bmj.b2535.
16. [16] Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. Higgins, J.P.T., Green, S., (eds.), 2009, The Cochrane Collaboration, London.
17. [17] Borenstein, M., Hedges, L., Higgins, J., Rothstein, H., Comprehensive Meta-analysis Version 2. 2005, Biostat., Englewood, NJ.
18. [18] Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 5, 2005, 13.
19. [19] Sutton, A.J., Abrams, K.R., Jones, D.R., Sheldon, T.A., Song, F., Methods for Meta-analysis in Medical Research. 2000, John Wiley & Sons, West Sussex.
20. [20] Ferretti, G., Bacchetti, T., Sahebkar, A., Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res. 60 (2015), 50–73, 10.1016/j.plipres.2015.08.003.
21. [21] Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res. 28 (2014), 633–642, 10.1002/ptr.5045.
22. [22] Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
23. [23] Gullestad, L., Jacobsen, T., Dolva, L.O., Effect of magnesium treatment on glycemic control and metabolic parameters in NIDDM patients. Diabetes Care 17 (1994), 460–461.
24. [24] de Valk, H.W., Verkaaik, R., van Rijn, H.J., Geerdink, R.A., Struyvenberg, A., Oral magnesium supplementation in insulin-requiring Type 2 diabetic patients. Diabet. Med. 15 (1998), 503–507.
25. [25] Paolisso, G., Scheen, A., Cozzolino, D., Di Maro, G., Varricchio, M., D'Onofrio, F., Lefebvre, P.J., Changes in glucose turnover parameters and improvement of glucose oxidation after 4-week magnesium administration in elderly noninsulin-dependent (type II) diabetic patients. J. Clin. Endocrinol. Metab. 78 (1994), 1510–1514.
26. [26] Paolisso, G., Sgambato, S., Gambardella, A., Pizza, G., Tesauro, P., Varricchio, M., D'Onofrio, F., Daily magnesium supplements improve glucose handling in elderly subjects. Am. J. Clin. Nutr. 55 (1992), 1161–1167.
27. [27] de Lordes Lima, M., Cruz, T., Pousada, J.C., Rodrigues, L.E., Barbosa, K., Canguçu, V., The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 21 (1998), 682–686.
28. [28] Eibl, N.L., Kopp, H.P., Nowak, H.R., Schnack, C.J., Hopmeier, P.G., Schernthaner, G., Hypomagnesemia in type II diabetes: effect of a 3-month replacement therapy. Diabetes Care 18 (1995), 188–192.
29. [29] Solati, M., Ouspid, E., Hosseini, S., Soltani, N., Keshavarz, M., Dehghani, M., Oral magnesium supplementation in type II diabetic patients. Med. J. Islam. Repub. Iran, 28, 2014, 67.
30. [30] Guerrero-Romero, F., Tamez-Perez, H.E., González-González, G., Salinas-Martínez, A.M., Montes-Villarreal, J., Treviño-Ortiz, J.H., Rodríguez-Morán, M., Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab. 30 (2004), 253–258.
31. [31] Lee, S., Park, H.K., Son, S.P., Lee, C.W., Kim, I.J., Kim, H.J., Effects of oral magnesium supplementation on insulin sensitivity and blood pressure in normo-magnesemic nondiabetic overweight Korean adults. Nutr. Metab. Cardiovasc. Dis. 19 (2009), 781–788, 10.1016/j.numecd.2009.01.002.
32. [32] Navarrete-Cortes, A., Ble-Castillo, J.L., Guerrero-Romero, F., Cordova-Uscanga, R., Juárez-Rojop, I.E., Aguilar-Mariscal, H., Tovilla-Zarate, C.A., Lopez-Guevara Mdel, R., No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia. Magnes. Res. 27 (2014), 48–56, 10.1684/mrh.2014.0361.
33. [33] Mooren, F.C., Krüger, K., Völker, K., Golf, S.W., Wadepuhl, M., Kraus, A., Oral magnesium supplementation reduces insulin resistance in non-diabetic subjects – a double-blind, placebo-controlled, randomized trial. Diabetes Obes. Metab. 13 (2011), 281–284, 10.1111/j.1463-1326.2010.01332.x.
34. [34] Cosaro, E., Bonafini, S., Montagnana, M., Danese, E., Trettene, M.S., Minuz, P., Delva, P., Fava, C., Effects of magnesium supplements on blood pressure, endothelial function and metabolic parameters in healthy young men with a family history of metabolic syndrome. Nutr. Metab. Cardiovasc. Dis. 24 (2014), 1213–1220, 10.1016/j.numecd.2014.05.010.
35. [35] Rodríguez-Moran, M., Guerrero-Romero, F., Oral magnesium supplementation improves the metabolic profile of metabolically obese, normal-weight individuals: a randomized double-blind placebo-controlled trial. Arch. Med. Res. 45 (2014), 388–393, 10.1016/j.arcmed.2014.05.003.
36. [36] Guerrero-Romero, F., Simental-Mendía, L.E., Hernández-Ronquillo, G., Rodriguez-Morán, M., Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial. Diabetes Metab. 41 (2015), 202–207, 10.1016/j.diabet.2015.03.010.
37. [37] Purvis, J.R., Cummings, D.M., Landsman, P., Carroll, R., Barakat, H., Bray, J., Whitley, C., Horner, R.D., Effect of oral magnesium supplementation on selected cardiovascular risk factors in non-insulin-dependent diabetics. Arch. Fam. Med. 3 (1994), 503–508.
38. [38] Lima de Souza, E., Silva Mde, L., Cruz, T., Rodrigues, L.E., Ladeia, A.M., Bomfim, O., Olivieri, L., Melo, J., Correia, R., Porto, M., Cedro, A., Magnesium replacement does not improve insulin resistance in patients with metabolic syndrome: a 12-week randomized double-blind study. J. Clin. Med. Res. 6 (2014), 456–462, 10.14740/jocmr1580w.
39. [39] Rodríguez-Morán, M., Guerrero-Romero, F., Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 26 (2003), 1147–1152.
40. [40] Barragán-Rodríguez, L., Rodríguez-Morán, M., Guerrero-Romero, F., Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes. Res. 21 (2008), 218–223.
41. [41] Guerrero-Romero, F., Rodríguez-Morán, M., The effect of lowering blood pressure by magnesium supplementation in diabetic hypertensive adults with low serum magnesium levels: a randomized, double-blind, placebo-controlled clinical trial. J. Hum. Hypertens. 23 (2009), 245–251, 10.1038/jhh.2008.129.
42. [42] Eriksson, J., Kohvakka, A., Magnesium and ascorbic acid supplementation in diabetes mellitus. Ann. Nutr. Metab. 39 (1995), 217–223.
43. [43] Chacko, S.A., Sul, J., Song, Y., Li, X., LeBlanc, J., You, Y., Butch, A., Liu, S., Magnesium supplementation, metabolic and inflammatory markers, and global genomic and proteomic profiling: a randomized, double-blind, controlled, crossover trial in overweight individuals. Am. J. Clin. Nutr. 93:2 (2011), 463–473, 10.3945/ajcn.110.002949.
44. [44] Kim, D.J., Xun, P., Liu, K., Loria, C., Yokota, K., Jacobs, D.R. Jr., He, K., Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. Diabetes Care 33 (2010), 2604–2610.
45. [45] Kao, W.H., Folsom, A.R., Nieto, F.J., Mo, J.P., Watson, R.L., Brancati, F.L., Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch. Intern. Med. 159 (1999), 2151–2159.
46. [46] Rumawas, M.E., McKeown, N.M., Rogers, G., Meigs, J.B., Wilson, P.W., Jacques, P.F., Magnesium intake is related to improved insulin homeostasis in the framingham offspring cohort. J. Am. Coll. Nutr. 25 (2006), 486–492.
47. [47] Ma, J., Folsom, A.R., Melnick, S.L., Eckfeldt, J.H., Sharrett, A.R., Nabulsi, A.A., Hutchinson, R.G., Metcalf, P.A., Associations of serum and dietary magnesium with cardiovascular disease, hypertension, diabetes, insulin, and carotid arterial wall thickness: the ARIC study. Atherosclerosis Risk in Communities Study. J. Clin. Epidemiol. 48 (1995), 927–940.
48. [48] Hopping, B.N., Erber, E., Grandinetti, A., Verheus, M., Kolonel, L.N., Maskarinec, G., Dietary fiber, magnesium, and glycemic load alter risk of type 2 diabetes in a multiethnic cohort in Hawaii. J. Nutr. 140 (2010), 68–74.
49. [49] Shi, Z.M., Hu, X.S., Yuan, B.J., Gibson, R., Dai, Y., Garg, M., Association between magnesium: iron intake ratio and diabetes in Chinese adults in Jiangsu Province. Diabet. Med. 25 (2008), 1164–1170.
50. [50] McKeown, N.M., Jacques, P.F., Zhang, X.L., Juan, W., Sahyoun, N.R., Dietary magnesium intake is related to metabolic syndrome in older Americans. Eur. J. Nutr. 47 (2008), 210–216.
51. [51] Ma, B., Lawson, A.B., Liese, A.D., Bell, R.A., Mayer-Davis, E.J., Dairy, magnesium, and calcium intake in relation to insulin sensitivity: approaches to modeling a dose-dependent association. Am. J. Epidemiol. 164 (2006), 449–458.
52. [52] Lopez-Ridaura, R., Willett, W.C., Rimm, E.B., Liu, S., Stampfer, M.J., Manson, J.E., Hu, F., Magnesium intake and risk of type 2 diabetes in men and women. Diabetes Care 27 (2004), 134–140.
53. [53] He, K., Liu, K., Daviglus, M.L., Morris, S.J., Loria, C.M., Van Horn, L., Jacobs, D.R. Jr., Savage, P.J., Magnesium intake and incidence of metabolic syndrome among young adults. Circulation 113 (2006), 1675–1682.
54. [54] Kirii, K., Iso, H., Date, C., Fukui, M., Tamakoshi, A., JACC Study Group, Magnesium intake and risk of self-reported type 2 diabetes among Japanese. J. Am. Coll. Nutr. 29 (2010), 99–106.
55. [55] Song, Y., Manson, J.E., Buring, J.E., Liu, S., Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in women. Diabetes Care 27 (2004), 59–65.
56. [56] Guerrero-Romero, F., Rodríguez-Morán, M., The role of magnesium in the pathogenesis of insulin resistance. Molière, Jocelyn, Gauthier, Lance, (eds.) Insulin Resistance: Symptoms, Causes and Treatment, 2010, Nova Science Publishers, Inc, NY U.S, 167–182.
57. [57] Gerich, J.E., Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch. Intern. Med. 163 (2003), 1306–1316.
58. [58] Blaine, J., Chonchol, M., Levi, M., Renal control of calcium, phosphate, and magnesium homeostasis. Clin. J. Am. Soc. Nephrol. 10 (2015), 1257–1272.
59. [59] Kowluru, A., Chen, H.Q., Modrick, L.M., Stefanelli, C., Activation of acetyl-CoA carboxylase by a glutamate- and magnesium-sensitive protein phosphatase in the islet beta-cell. Diabetes 50 (2001), 1580–1587.
60. [60] Murakami, M., Ishizuka, J., Sumi, S., Nickols, G.A., Cooper, C.W., Townsend, C.M. Jr., Thompson, J.C., Role of extracellular magnesium in insulin secretion from rat insulinoma cells. Proc. Soc. Exp. Biol. Med. 200 (1992), 490–494.
61. [61] Ishizuka, J., Bold, R.J., Townsend, C.M. Jr., Thompson, J.C., In vitro relationship between magnesium and insulin secretion. Magnes. Res. 7 (1994), 17–22.
62. [62] Matsunobu, S., Terashima, Y., Senshu, T., Sano, H., Itoh, H., Insulin secretion and glucose uptake in hypomagnesemic sheep fed a low magnesium, high potassium diet. J. Nutr. Biochem. 1 (1990), 167–171.
63. [63] Curry, D.L., Joy, R.M., Holley, D.C., Bennett, L.L., Magnesium modulation of glucose-induced insulin secretion by the perfused rat pancreas. Endocrinology 101 (1977), 203–208.
64. [64] Simental-Mendía, L.E., Rodríguez-Morán, M., Guerrero-Romero, F., Failure of β-cell function for compensate variation in insulin sensitivity in the hypomagnesemic subjects. Magnes. Res. 22 (2009), 151–156.
65. [65] Rodríguez-Morán, M., Guerrero-Romeo, F., Insulin secretion is decreased in non-diabetic individuals with hypomagnesemia. Diabetes Metab. Res. Rev. 27 (2011), 590–596.
66. [66] Guerrero-Romero, F., Rodríguez-Morán, M., Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial. Eur. J. Clin. Invest. 41 (2011), 405–410, 10.1111/j.1365-2362.2010.02422.x.
67. [67] Rylander, R., Bioavailability of magnesium salts—a review. J. Pharm. Nutr. Sci. 4 (2014), 57–59.